Becton Dickinson and Co (BDX) : Busey Trust Co scooped up 80 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 59,008 shares of Becton Dickinson and Co which is valued at $10,266,212.Becton Dickinson and Co makes up approximately 1.28% of Busey Trust Co’s portfolio.
Other Hedge Funds, Including , Colony Group boosted its stake in BDX in the latest quarter, The investment management firm added 915 additional shares and now holds a total of 7,549 shares of Becton Dickinson and Co which is valued at $1,313,375. Becton Dickinson and Co makes up approx 0.15% of Colony Group’s portfolio.First Personal Financial Services boosted its stake in BDX in the latest quarter, The investment management firm added 417 additional shares and now holds a total of 827 shares of Becton Dickinson and Co which is valued at $143,501. Becton Dickinson and Co makes up approx 0.05% of First Personal Financial Services’s portfolio.First National Trust Co boosted its stake in BDX in the latest quarter, The investment management firm added 233 additional shares and now holds a total of 1,704 shares of Becton Dickinson and Co which is valued at $297,399. Becton Dickinson and Co makes up approx 0.04% of First National Trust Co’s portfolio.Regentatlantic Capital reduced its stake in BDX by selling 98 shares or 2.11% in the most recent quarter. The Hedge Fund company now holds 4,538 shares of BDX which is valued at $797,690. Becton Dickinson and Co makes up approx 0.07% of Regentatlantic Capital’s portfolio.
Becton Dickinson and Co closed down -0.19 points or -0.11% at $177.02 with 6,09,017 shares getting traded on Thursday. Post opening the session at $177.71, the shares hit an intraday low of $175.71 and an intraday high of $177.78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.